Skip to content
Rare Medication

Shortage status

Haloperidol Decanoate shortage - supply and sourcing support

Being withdrawn.

Haloperidol Decanoate is listed by the FDA as to be discontinued.

FDA status
To Be Discontinued
Affected form
Injection
FDA updated
01/09/2026

Presentations listed by the FDA

2

Source: FDA drug shortage database - checked 20 Sept 2026 - open the FDA record

A shortage rarely means a medicine has vanished. Usually one presentation is short while others keep shipping, and how long it lasts depends on why it started. Below is what is known about Haloperidol Decanoate supply right now, what tends to be affected, and what you can do about it today. When a medicine is short, manufacturers and regulators publish notices as supply changes. Those notices are what this page tracks, and they lag reality by days rather than hours.

What to do now

  1. 1Ask your prescriber to plan the switch early, while the current presentation is still around.
  2. 2Ask your pharmacy how much stock the wholesaler still holds for this presentation.
  3. 3If continuity matters and no alternative fits, tell us and we will check what is still sourceable.
Ask us to find it

What usually goes short, and what does not

Shortages hit a presentation, not an ingredient: one strength, one pack size, or one manufacturer's line. A different strength of the same medicine, or the same strength from another maker, is often still available, which is why the first question to a pharmacy is not «do you have it» but «which of these do you have».

Shortage-related searches for Haloperidol Decanoate are best handled with clear governance: confirm the product, confirm alternatives under policy, then route a structured B2B request if appropriate.

We do not guarantee supply. Any follow-up is subject to product eligibility, licensing, and market conditions.

Market signals and documentation

Confirm the International Nonproprietary Name (INN) for your request: Haloperidol Decanoate. Trade names and pack sizes vary by market.

Therapeutic context often referenced in procurement for this entry: Neurology. This does not replace clinical protocols.

For quotation review, teams typically prepare: strength, dosage form, pack size, destination country, and organization billing or licensing identifiers as required by your process.

A submitted inquiry does not create a contractual obligation to supply and does not replace approvals required by your institution or regulators.

Trust: compliant shortage support

Shortage pressure should not push buyers toward informal channels. Rare Medication focuses on compliant sourcing support for eligible organizations - not informal sellers or unverified brokers.

  • If a request cannot proceed, you should receive a clear outcome rather than ambiguous promises.
  • Procurement questions related to Haloperidol Decanoate are reviewed in line with authorized wholesale norms and destination-country rules.
  • We do not facilitate unlicensed sales, personal import for resale, or circumvention of prescribing rules.
  • If follow-up is possible, it should stay within authorized wholesale and documentation norms for your jurisdiction.

Request availability for your organization

Next step: Submit a procurement inquiry for licensed-organization review. Include organization context so reviewers can assess feasibility responsibly. No payment or purchase obligation at submission.

Why teams use structured shortage inquiries

When usual channels are constrained, a clear procurement request helps reviewers assess feasibility without bypassing law or institutional controls.

  • Licensed healthcare organizations and professional procurement contacts only
  • Quotation-based review - no obligation and no guaranteed allocation
  • Documentation expectations explained during follow-up where applicable
  • Aligned with distributor advisories and your local compliance rules

Frequently asked questions